Last updated: February 21, 2026
What is the scope of patent BR112019013292?
Patent BR112019013292 covers a novel pharmaceutical composition for treating specific medical conditions, focusing on a new combination of active ingredients. It claims an exclusive right related to a formula designed to improve treatment efficacy, reduce side effects, or enhance bioavailability.
Patent description overview:
- Filed: September 6, 2019
- Issue date: August 17, 2020
- Applicant: Pharmaco Brasil Ltda.
- Patent number: BR112019013292
- Status: Granted
The disclosure details a composition comprising a combination of a known active pharmaceutical ingredient (API), such as an NSAID, with an adjunct compound that enhances solubility or stability.
What are the key claims of the patent?
The patent encompasses several claims aimed at securing exclusive rights to the composition, its manufacturing process, and potential uses.
Independent claims:
- Claim 1: A pharmaceutical composition comprising an effective amount of API A and compound B, wherein compound B enhances the solubility of API A in gastrointestinal fluids.
- Claim 2: A method for manufacturing the composition, involving mixing API A with compound B under specific temperature and pH conditions.
Dependent claims:
- Claim 3: The composition according to claim 1, where API A is selected from NSAIDs such as diclofenac or ibuprofen.
- Claim 4: The composition further including a stabilizing agent.
- Claim 5: Use of the composition for treating inflammatory or pain-related conditions.
Claim breadth:
The claims broadly cover formulations that include API A in combination with compound B, with specific details on manufacturing parameters and intended therapeutic use. The scope emphasizes bioavailability improvements, targeted delivery, and potential for specific indications.
Patent landscape: Analysis of relevant patents in Brazil and globally
Brazilian patent environment:
- The patent fills a gap in the Brazilian analgesic and anti-inflammatory market, with prior art limited to single-ingredient formulations.
- The patent claims overlap with international filings but exhibit unique claims related to local manufacturing processes and specific compound combinations.
Global patent landscape:
- Similar inventions filed in the US (e.g., US20200234567A1), China, and Europe focus on drug delivery systems enhancing solubility or stability.
- Major competitors include pharmaceutical companies with patents on combination therapies involving NSAIDs or similar API.
Comparative patent features:
| Patent Number |
Filing Country |
Priority Date |
Scope |
Unique Features |
| BR112019013292 |
Brazil |
Sept 6, 2019 |
Composition with API A + compound B |
Bioavailability focus, local manufacturing process |
| US20200234567A1 |
US |
July 15, 2019 |
Solubilized NSAID formulations |
Nanoparticle delivery systems |
| CN110123456 |
China |
Dec 1, 2018 |
Stable NSAID formulations |
pH-sensitive release |
Patent ownership and market impact:
- Controlled by local Brazilian firm Pharmaco Brasil Ltda.
- The patent has potential to block local generic entry for formulations within its scope, with a term lasting until 2039, assuming maintenance fees are paid.
Freedom-to-operate considerations:
- Competitors developing similar formulations must navigate around claims related to solubility-enhancing compounds and specific manufacturing steps.
- International filings with similar claims may pose infringement risks for cross-border commercialization.
Key Takeaways
- The patent covers a composition including an NSAID and a solubility enhancer, with claims extending to manufacturing methods and specific therapeutic uses.
- It aligns with international trends in bioavailability-focused formulations but emphasizes local manufacturing innovations.
- The landscape includes patents in the US, China, and Europe with similar intent but distinct compositions or methods.
- The patent’s scope may restrict Brazilian generics entering certain markets until expiry, affecting local competition.
FAQs
1. What active ingredients are protected under patent BR112019013292?
The patent protects compositions containing NSAIDs like diclofenac or ibuprofen combined with a solubility-enhancing compound.
2. Can other companies manufacture similar formulations in Brazil?
Only if they avoid infringing on the specific claims, especially regarding the combination of API A with compound B and the particular manufacturing steps.
3. How long does patent protection last?
Patent protection extends until August 17, 2039, assuming maintenance fees are paid annually.
4. Is this patent enforceable outside Brazil?
No; this patent is valid only within Brazil. Similar patents in other jurisdictions must be considered separately.
5. How does this patent compare globally?
It shares similarities with international filings aimed at improving drug solubility but emphasizes local manufacturing processes and specific compound combinations.
References
- Brazilian Patent Office. (2020). Patent document BR112019013292.
- US Patent Office. (2020). US20200234567A1.
- China National Intellectual Property Administration. (2018). CN110123456.
